EU and US could reach trade deal this weekend - Reuters
On Monday, Benchmark analysts maintained a Speculative Buy rating on Reviva Pharmaceuticals (NASDAQ:RVPH) with a steady price target of $14.00, representing significant upside potential from the current price of $1.03. According to InvestingPro data, analyst targets for the stock range from $3.00 to $16.00, with a strong consensus recommendation of 1.5. The firm’s analysts highlighted the upcoming participation of Reviva Pharmaceuticals in the 5th Annual Benchmark Virtual Healthcare Investor Conference scheduled for May 29, 2025, encouraging interested parties to contact their Benchmark account executive for further details.
Reviva Pharmaceuticals, which concluded the quarter with a cash balance of $13.5 million, is anticipated to require additional funding to progress its clinical programs. While InvestingPro analysis shows the company holds more cash than debt on its balance sheet, its current ratio of 0.54 indicates short-term obligations exceed liquid assets. With a market capitalization of $48.14 million and an overall Financial Health Score rated as ’Weak’, the company is considering various avenues, including partnerships and licensing opportunities, to secure the necessary capital. Analysts pointed out three significant forthcoming events for Reviva’s stock: the release of the full dataset from the ongoing open-label extension (OLE) trial expected in the second quarter of 2025, the commencement of the RECOVER-2 Trial around mid-2025, and the planned submission of a New Drug Application (NDA) for Brilaroxazine for the treatment of schizophrenia in the fourth quarter of 2026.
The analysts expressed a positive outlook on Brilaroxazine, noting its demonstrated advantages over existing schizophrenia treatments. According to the data, Brilaroxazine has shown to be more effective, with fewer side effects, higher patient compliance, and simpler dosing. These attributes potentially make it a compelling candidate for partnerships within the pharmaceutical industry, as per Benchmark’s analysis.
The company’s pursuit of additional capital and strategic partnerships is geared towards advancing its clinical programs and bringing its therapeutic candidates, like Brilaroxazine, closer to market approval and commercialization. Discover more insights about RVPH’s financial health, including 8 additional ProTips and comprehensive financial metrics, with InvestingPro’s advanced analysis tools.
In other recent news, Reviva Pharmaceuticals has experienced notable adjustments in its stock evaluations by two analyst firms. Boral (OTC:BOALY) Capital has significantly reduced its price target for Reviva from $8.00 to $3.00, maintaining a Buy rating despite concerns over the company’s financial position. The firm highlighted the potential advancement of Reviva’s lead drug candidate, brilaroxazine, but expressed worries about the company’s cash reserves, which may not suffice for upcoming milestones. Meanwhile, Benchmark has also lowered its price target for Reviva from $17 to $14, maintaining a Speculative Buy rating. This adjustment was influenced by the updated share count in Reviva’s 10-K filing. Reviva concluded the quarter with $13.5 million in cash reserves, but additional funding may be necessary to support its clinical programs. The company is expected to pursue partnership and licensing opportunities to secure the required capital. Analysts from Benchmark noted that brilaroxazine might offer better efficacy and fewer side effects compared to existing treatments for schizophrenia, making it attractive for potential partners.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.